169 related articles for article (PubMed ID: 21241513)
1. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR
Virol J; 2011 Jan; 8():22. PubMed ID: 21241513
[TBL] [Abstract][Full Text] [Related]
2. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.
Au GG; Lindberg AM; Barry RD; Shafren DR
Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
Shafren DR; Au GG; Nguyen T; Newcombe NG; Haley ES; Beagley L; Johansson ES; Hersey P; Barry RD
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):53-60. PubMed ID: 14734451
[TBL] [Abstract][Full Text] [Related]
4. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
[TBL] [Abstract][Full Text] [Related]
5. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
Skelding KA; Barry RD; Shafren DR
Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
10. Talimogene laherparepvec (Imlygic) for unresectable melanoma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):8-9. PubMed ID: 26761342
[No Abstract] [Full Text] [Related]
11. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
12. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
13. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
14. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
15. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.
Skelding KA; Barry RD; Shafren DR
Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929
[TBL] [Abstract][Full Text] [Related]
16. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
Jiang H; Shin DH; Nguyen TT; Fueyo J; Fan X; Henry V; Carrillo CC; Yi Y; Alonso MM; Collier TL; Yuan Y; Lang FF; Gomez-Manzano C
Clin Cancer Res; 2019 Nov; 25(22):6801-6814. PubMed ID: 31455679
[TBL] [Abstract][Full Text] [Related]
17. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.
Hadac EM; Kelly EJ; Russell SJ
Mol Ther; 2011 Jun; 19(6):1041-7. PubMed ID: 21505425
[TBL] [Abstract][Full Text] [Related]
18. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins.
Colunga AG; Laing JM; Aurelian L
Gene Ther; 2010 Mar; 17(3):315-27. PubMed ID: 19798049
[TBL] [Abstract][Full Text] [Related]
19. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
20. Applications of coxsackievirus A21 in oncology.
Bradley S; Jakes AD; Harrington K; Pandha H; Melcher A; Errington-Mais F
Oncolytic Virother; 2014; 3():47-55. PubMed ID: 27512662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]